Importantly, NDUFS1 is well-known to convert NADH into NAD+ while accumulation of NAD+ in pulmonary epithelial cells by treatment with Olaparib, the clinical available PARP inhibitor promotion of NAD+ accumulation, normalized the reduced expression of ENaCα and lung damage during ALI. Here, NDUFS1 is linked to acute respiratory distress syndrome.